Phalanx Labs banned from shipping APIs to US after refusing inspection

By Gareth Macdonald

- Last updated on GMT

Phalanx Labs' site in Visakhapatnam, India banned by US FDA
Phalanx Labs' site in Visakhapatnam, India banned by US FDA

Related tags Erectile dysfunction drugs Active pharmaceutical ingredients Pharmaceutical drug

The US FDA has banned Phalanx Labs from shipping products to the US after the Indian API and intermediates firm refused to let inspectors visit its site in Visakhapatnam.

The US regulator added Phalanx to its import alert list​ – also known as the Red List - on Wednesday and suggested the firm’s refusal to allow an agency team to visit its site could indicate manufacturing operations are not up to code.

The refusal to permit inspection of a foreign facility or provide reasonable access to FDA’s inspectional personnel, combined with other evidence, provides an appearance that the firm’s products are manufactured, processed, or packed under insanitary conditions​.”

The facility – identified as Plot No.74B – produces 15 active pharmaceutical ingredients (API) – including those for erectile dysfunction drugs, ulcer medications and anticoagulants – and chemical intermediates according to the privately-owned firm’s website.

The site also provides contract manufacturing services for APIs and chemical intermediates. 

At the time of publication, Phalanx's websites states that its manufacturing operations comply with “regulatory requirements of various prominent international regulatory bodies, including Europe and US​.”

The firm also states the plant is ISO 9001-2008 compliant, accredited by Japan’s Ministry of Health, Labour and Welfare (MoH) and the WHO and has been issued with “written confirmation” of quality needed to ship APIs to the European Union.

Phalanx did not respond to a request for comment.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more